Journal
EUROPEAN JOURNAL OF CANCER
Volume 75, Issue -, Pages 141-149Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2017.01.004
Keywords
Programmed death-ligand 1; Pulmonary adenocarcinoma; Immune checkpoint; PD-1 blockade; Cancer immunotherapy
Categories
Funding
- National Research Foundation (NRF) for the Global Core Research Center (GCRC) - Ministry of Science, ICT and Future Planning (MSIP) [2016005276]
- Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI14C0069]
Ask authors/readers for more resources
Programmed death-ligand 1 (PD-L1) expression in pulmonary adenocarcinomas (pADCs) was implicated in predicting anti-PD-1/PD-L1 therapy efficacy. However, the differential expression of PD-L1 between primary and metastatic pADC remains unclear. Thus, we addressed this issue. In total, 161 paired primary and metastatic tumour tissues from 146 patients with pADC were collected. Most of the cases had regional nodal metastasis (134/161, 83.2%). PD-L1 expression was categorised based on the proportion of immunostained tumour cells using cutoff values of 1%, 5%, 10% and 50%. In primary tumours, PD-L1 positivity was observed in 28.1% (41/146), 27.4% (40/146), 22.6%.(33/146) and 13.0% (19/146) of cases using cutoff values of 1%, 5%, 10% and 50%, respectively. The overall concordance rate for PD-L1 expression between primary and metastatic tumours was 75.2% (121/161). The concordance rate in primary tumours expressing PD-L1 in <1% or >= 50% of tumour cells was 87.2% (102/117) or 70% (14/20), respectively. In contrast, the concordance rate in tumours expressing PD-Ll in >= 1% to <50% of cells was only 20.8% (5/24). After dichotomising the cases using cutoff values of 1% and 50%, the concordance rate increased to 80.1% (129/161) and 90.7% (146/161) in all paired cases and to 70.4% (19/27) and 85.2% (23/27) in cases with distant metastases, respectively. This study demonstrates that the concordance of PD-Ll expression between primary and metastatic pADC is high when using cutoff values of 1% and 50%. Thus, evaluation of PD-Ll in either primary or metastatic tumours would be helpful for guiding anti-PD-1/PD-L1 immunotherapy in patients with advanced pADC. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available